Aromatase Inhibitors Cost-Effective Compared To Tamoxifen, NICE Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
Although an overall survival advantage has not been shown, the U.K. agency recommends coverage of Arimidex, Aromasin and Femara.